Moderna’s RSV Vaccine Trials Halted Over Alarming Safety Signals in Children – A Wake-Up Call on Vaccine Development EthicsIn December 2024, a shocking headline emerged: “Safety signal in Moderna’s RSV vaccine studies halts trials of other vaccines for childhood killer.”

Moderna’s mRNA-based RSV vaccines, intended to protect infants, not only failed to safeguard them but may have made some children sicker when infected with RSV or other respiratory viruses. This disturbing finding, discussed at the FDA’s VRBPAC committee meeting under the Biden administration, reveals critical flaws in the rush to develop RSV vaccines for children.

The data is sobering. In Moderna’s phase 1 trial, five infants (12.5%) who received mRNA-1345 or mRNA-1365 developed severe or very severe RSV lower respiratory tract infections, compared to just one (5%) in the placebo group. Four of these children were hospitalized, one requiring mechanical ventilation.

Moderna paused the trial in July 2024, and the FDA subsequently halted all RSV vaccine trials for infants under 2 and RSV-naive children aged 2-5.VRBPAC’s discussion was revealing. One committee member admitted, “We don’t really understand the mechanism why” these vaccines might worsen disease.

Despite rigorous safety protocols, the safeguards failed to predict severe outcomes. This echoes a warning from Dr. Peter Hotez in 2020 about rushing coronavirus vaccines: upper respiratory vaccines can sometimes exacerbate disease, and science still doesn’t fully understand why.

This isn’t a new problem. Since the 1960s, RSV vaccine development has been plagued by disease enhancement, where vaccines paradoxically worsen the illness they aim to prevent. Historical trials saw tragic outcomes, including child deaths, yet the push for an RSV vaccine persists, driven by a projected $2 billion market in 2024 and a potential $15 billion by 2030.

Meanwhile, monoclonal antibody trials for RSV, like those recently approved, have also raised concerns, with three infant deaths reported. The ethical questions are glaring. Why are children being enrolled in trials when the underlying immune mechanisms remain a mystery? Why do regulatory agencies continue to greenlight studies despite decades of evidence showing unpredictable risks?

Critics argue this reflects a pharmaceutical industry more focused on profit than patient safety, with regulatory bodies complicit in allowing trials to proceed without fully understanding the science. This pattern—rushing vaccines despite known risks—isn’t unique to RSV.

The VRBPAC’s admission of ignorance about why these vaccines cause harm should be a red flag for anyone trusting in the infallibility of regulatory science. As one committee member noted, they’re “hopeful” Moderna’s further investigations will shed light.

But hope isn’t a strategy when children’s lives are at stake. The public deserves answers. How can trials continue when the immune system’s response to these vaccines remains so poorly understood? Where is the accountability for regulatory agencies that approve studies despite such risks?

And why does the promise of billions in revenue seem to outweigh the caution needed to protect vulnerable children?This is a call to rethink the blind faith in pharmaceutical solutions and demand transparency, rigorous science, and ethical accountability. The stakes couldn’t be higher.

@DelBigtree